| Yap1 acts downstream of α-catenin to control epidermal proliferation K Schlegelmilch, M Mohseni, O Kirak, J Pruszak, JR Rodriguez, D Zhou, ... Cell 144 (5), 782-795, 2011 | 1095 | 2011 |
| AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer D Hong, R Kurzrock, Y Kim, R Woessner, A Younes, J Nemunaitis, ... Science translational medicine 7 (314), 314ra185-314ra185, 2015 | 436 | 2015 |
| Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer M Mori, R Triboulet, M Mohseni, K Schlegelmilch, K Shrestha, ... Cell 156 (5), 893-906, 2014 | 381 | 2014 |
| A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway M Mohseni, J Sun, A Lau, S Curtis, J Goldsmith, VL Fox, C Wei, M Frazier, ... Nature cell biology 16 (1), 108-117, 2014 | 332 | 2014 |
| Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis Z Cai, JJ Kotzin, B Ramdas, S Chen, S Nelanuthala, LR Palam, R Pandey, ... Cell stem cell 23 (6), 833-849. e5, 2018 | 290 | 2018 |
| Tumor‐propagating cells and Y ap/T az activity contribute to lung tumor progression and metastasis AN Lau, SJ Curtis, CM Fillmore, SP Rowbotham, M Mohseni, DE Wagner, ... The EMBO journal 33 (5), 468-481, 2014 | 237 | 2014 |
| SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors L Dardaei, HQ Wang, M Singh, P Fordjour, KX Shaw, S Yoda, G Kerr, ... Nature medicine 24 (4), 512-517, 2018 | 185 | 2018 |
| Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer MJ LaMarche, M Acker, A Argintaru, D Bauer, J Boisclair, H Chan, ... Journal of medicinal chemistry 63 (22), 13578-13594, 2020 | 128 | 2020 |
| Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition JR LaRochelle, M Fodor, V Vemulapalli, M Mohseni, P Wang, T Stams, ... Nature communications 9 (1), 4508, 2018 | 124 | 2018 |
| Dematin and adducin provide a novel link between the spectrin cytoskeleton and human erythrocyte membrane by directly interacting with glucose transporter-1 AA Khan, T Hanada, M Mohseni, JJ Jeong, L Zeng, M Gaetani, D Li, ... Journal of biological chemistry 283 (21), 14600-14609, 2008 | 111 | 2008 |
| Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling C Liu, H Lu, H Wang, A Loo, X Zhang, G Yang, C Kowal, S Delach, ... Clinical Cancer Research 27 (1), 342-354, 2021 | 106 | 2021 |
| 6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors P Sarver, M Acker, JT Bagdanoff, Z Chen, YN Chen, H Chan, B Firestone, ... Journal of medicinal chemistry 62 (4), 1793-1802, 2019 | 83 | 2019 |
| SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors H Lu, C Liu, R Velazquez, H Wang, LM Dunkl, M Kazic-Legueux, ... Molecular cancer therapeutics 18 (7), 1323-1334, 2019 | 76 | 2019 |
| Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2 JR LaRochelle, M Fodor, JM Ellegast, X Liu, V Vemulapalli, M Mohseni, ... Bioorganic & medicinal chemistry 25 (24), 6479-6485, 2017 | 52 | 2017 |
| SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms Y Wang, M Mohseni, A Grauel, JE Diez, W Guan, S Liang, JE Choi, M Pu, ... Scientific reports 11 (1), 1399, 2021 | 46 | 2021 |
| Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers HX Hao, H Wang, C Liu, S Kovats, R Velazquez, H Lu, B Pant, M Shirley, ... Molecular cancer therapeutics 18 (12), 2368-2380, 2019 | 39 | 2019 |
| Nicotinamide phosphoribosyltransferase inhibitor as a novel payload for antibody–drug conjugates AS Karpov, T Abrams, S Clark, A Raikar, JA D’Alessio, MP Dillon, ... ACS medicinal chemistry letters 9 (8), 838-842, 2018 | 35 | 2018 |
| SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations R Pandey, B Ramdas, C Wan, G Sandusky, M Mohseni, C Zhang, ... The Journal of clinical investigation 129 (12), 5468-5473, 2019 | 34 | 2019 |
| Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR H Lu, C Liu, H Huynh, TBU Le, MJ LaMarche, M Mohseni, JA Engelman, ... Oncotarget 11 (3), 265, 2020 | 31 | 2020 |
| Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations B Ladd, AM Mazzola, T Bihani, Z Lai, J Bradford, M Collins, E Barry, ... Oncotarget 7 (34), 54120, 2016 | 25 | 2016 |
